Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Timothy A. Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren, Luana Calabrò, Ronnie Shapira‐Frommer, Bo Gao, Steven Kao, Ignacio Matos, David Planchard, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Hedy L. Kindler
Topics & Concepts
PembrolizumabMedicineInternal medicineClinical endpointResponse Evaluation Criteria in Solid TumorsCohortMesotheliomaClinical trialOncologyAdverse effectPhases of clinical researchSurgeryCancerPathologyImmunotherapyOccupational and environmental lung diseasesCancer Immunotherapy and BiomarkersPleural and Pulmonary Diseases